Thomas A Fitzgerald insider trades: Transcode Therapeutics (RNAZ) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Thomas reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 28, 2023 | RNAZ | ↑ Buy | 49,350 | $0.51 | $25K | Direct | Oct 2, 2023 (4d) |
| Jun 16, 2022 | RNAZ | ↑ Buy | 12,000 | $1.27 | $15K | Direct | Jun 17, 2022 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Thomas A Fitzgerald's insider trades
Thomas A Fitzgerald is Chief Financial Officer at Transcode Therapeutics (RNAZ). Since Jun 16, 2022, Thomas has reported 2 open-market purchases worth $40K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RNAZ insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.